{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:51Z","timestamp":1794273891795,"version":"4.9.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Promising results have been reported for adult patients with high-risk hematologic malignancies undergoing haploidentical bone marrow transplant (haploBMT) with posttransplant cyclophosphamide (PTCy). To our knowledge, we report results from the first multicenter trial for pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndrome (MDS) in the Pediatric Transplantation and Cellular Therapy Consortium. Nine centers performed transplants in 32 patients having acute leukemias or MDS, with myeloablative conditioning (MAC), haploBMT with PTCy, mycophenolate mofetil, and tacrolimus. The median patient age was 12 years. Diagnoses included AML (15), ALL (11), mixed-lineage leukemia (1), and MDS (5). Transplant-related mortality (TRM) at 180 days was 0%. The cumulative incidence (CuI) of grade 2 acute graft-versus-host disease (aGVHD) on day 100 was 13%. No patients developed grades 3-4 aGVHD. The CuI of moderate-to-severe chronic GVHD (cGVHD) at 1 year was 4%. Donor engraftment occurred in 27 patients (84%). Primary graft failures included 3 patients who received suboptimal bone marrow grafts; all successfully engrafted after second transplants. The CuI of relapse at 1 year was 32%, with more relapse among patients MRD positive pre-BMT vs MRD negative. Overall survival rates at 1 and 2 years were 77% and 73%, and event-free survival rate at 1 and 2 years were 68% and 64%. There was no TRM or severe aGVHD, low cGVHD, and favorable relapse and survival rates. This successful pilot trial has led to a phase 3 trial comparing MAC haploBMT vs HLA-matched unrelated donor BMT in the Children\u2019s Oncology Group. This trial was registered at www.clinicaltrials.gov as #NCT02120157.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010281","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:03:52Z","timestamp":1685552632000},"page":"5639-5648","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-8237","authenticated-orcid":false,"given":"Juan C.","family":"Fierro-Pineda","sequence":"first","affiliation":[{"name":"1Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"2Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"1Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Blackford","sequence":"additional","affiliation":[{"name":"1Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cluster","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Caywood","sequence":"additional","affiliation":[{"name":"4Nemours Center for Cancer and Blood Disorders, Nemours Children\u2019s Health, Wilmington, DE; Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Dalal","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Hematology\/Oncology\/Bone Marrow Transplant, Rainbow Babies and Children\u2019s Hospital, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Davis","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology\/BMT, Department of Pediatrics, BC Children\u2019s Hospital, University of British Columbia, Vancouver, BC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Egeler","sequence":"additional","affiliation":[{"name":"7Hospital for Sick Children, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-9118","authenticated-orcid":false,"given":"Jeffrey","family":"Huo","sequence":"additional","affiliation":[{"name":"8Pediatric Blood and Marrow Transplant and Cellular Therapies, Atrium Health Levine Children's Hospital, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hudspeth","sequence":"additional","affiliation":[{"name":"9Division of Pediatric Hematology, Oncology, and BMT, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Keating","sequence":"additional","affiliation":[{"name":"10Pediatric Blood and Marrow Transplant and Cellular Therapeutics, University of Colorado School of Medicine, and The Children\u2019s Hospital of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"11AdventHealth for Children, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Krueger","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, Bone Marrow Transplant\/Cell Therapy Section, SickKids, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean","family":"Lee","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Oncology, and BMT, Nationwide Children\u2019s Hospital and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lehmann","sequence":"additional","affiliation":[{"name":"14Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Madden","sequence":"additional","affiliation":[{"name":"15Texas Transplant Institute, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Oshrine","sequence":"additional","affiliation":[{"name":"16Cancer and Blood Disorders Institute, Johns Hopkins All Children\u2019s Hospital, Saint Petersburg, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"17Intermountain Primary Children\u2019s Hospital Division of Hematology, Oncology, and BMT, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry","family":"Fry","sequence":"additional","affiliation":[{"name":"10Pediatric Blood and Marrow Transplant and Cellular Therapeutics, University of Colorado School of Medicine, and The Children\u2019s Hospital of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[{"name":"1Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"7","key":"2023092719103517500_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023092719103517500_bib2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2020.06.012","article-title":"Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study","volume":"26","author":"Paul","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023092719103517500_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023092719103517500_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2023092719103517500_bib5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a t cell replete graft compared with t cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023092719103517500_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023092719103517500_bib7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using t cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023092719103517500_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023092719103517500_bib9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2023092719103517500_bib10","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.jtct.2021.11.002","article-title":"Umbilical cord blood or HLA-haploidentical transplantation: real-world outcomes versus randomized trial outcomes","volume":"28","author":"O'Donnell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2023092719103517500_bib11","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for t-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023092719103517500_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41409-021-01551-z","article-title":"Results of a multicenter phase I\/II trial of TCR\u03b1\u03b2 and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients","volume":"57","author":"Bethge","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023092719103517500_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2023092719103517500_bib14","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood.2022015959","article-title":"KIR-favorable TCR-\u03b1\u03b2\/CD19-depleted haploidentical HCT in children with ALL\/AML\/MDS: primary analysis of the PTCTC ONC1401 trial","volume":"140","author":"Pulsipher","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2023092719103517500_bib15","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2023092719103517500_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/pbc.25352","article-title":"Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability","volume":"62","author":"Shook","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2023092719103517500_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"26","key":"2023092719103517500_bib18","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2023092719103517500_bib19","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the European society for blood and marrow transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023092719103517500_bib20","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2023092719103517500_bib21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2023092719103517500_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023092719103517500_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","article-title":"Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT","volume":"9","author":"Rubio","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"2023092719103517500_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-020-01063-2","article-title":"Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia","volume":"56","author":"Saglio","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023092719103517500_bib25","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.jtct.2022.01.002","article-title":"Post-transplantation cyclophosphamide-based haploidentical versus matched unrelated donor peripheral blood hematopoietic stem cell transplantation using myeloablative targeted busulfan-based conditioning for pediatric acute leukemia","volume":"28","author":"Hong","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023092719103517500_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bbmt.2016.12.640","article-title":"Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy","volume":"23","author":"Majzner","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2023092719103517500_bib27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","article-title":"Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023092719103517500_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fped.2020.00282","article-title":"T-cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies","volume":"8","author":"Katsanis","year":"2020","journal-title":"Front Pediatr"},{"issue":"1","key":"2023092719103517500_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2023092719103517500_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/petr.12658","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study","volume":"20","author":"Yesilipek","year":"2016","journal-title":"Pediatr Transplant"},{"issue":"2","key":"2023092719103517500_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","article-title":"Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies","volume":"23","author":"Klein","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023092719103517500_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbmt.2015.11.010","article-title":"Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-busulfan-and melphalan-based conditioning","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023092719103517500_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.25661","article-title":"Haploidentical transplantation in high-risk pediatric leukemia: a retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)","volume":"95","author":"P\u00e9rez-Mart\u00ednez","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"2023092719103517500_bib34","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbmt.2016.02.002","article-title":"Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study","volume":"22","author":"Berger","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2023092719103517500_bib35","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2023092719103517500_bib36","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1097\/MPH.0000000000002030","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for pediatric acute leukemia is safe and effective","volume":"43","author":"Sharma","year":"2021","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"10","key":"2023092719103517500_bib37","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2018.06.007","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide\/bendamustine in pediatric and young adult patients with hematologic malignancies","volume":"24","author":"Katsanis","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023092719103517500_bib38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023092719103517500_bib39","unstructured":"BMT-CTN\n              \n            \n          . Technical Manual of Procedures. Version 3.0. Accessed 19 March 2013. https:\/\/web.emmes.com\/study\/bmt2\/public\/MOP\/BMT%20CTN%20Technical%20MOP%20v3.pdf."},{"issue":"3","key":"2023092719103517500_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann Stat"},{"issue":"3","key":"2023092719103517500_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"2023092719103517500_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"7","key":"2023092719103517500_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020009342","article-title":"A\u00a0validated pediatric disease risk index for allogeneic hematopoietic cell transplantation","volume":"137","author":"Qayed","year":"2021","journal-title":"Blood"},{"issue":"18","key":"2023092719103517500_bib44","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","article-title":"One-unit versus two-unit cord-blood transplantation for hematologic cancers","volume":"371","author":"Wagner","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023092719103517500_bib45","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023092719103517500_bib46","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/bloodadvances.2018025908","article-title":"The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2023092719103517500_bib47","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2008-07-163238","article-title":"Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors","volume":"113","author":"MacMillan","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2023092719103517500_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2023092719103517500_bib49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int J Hematol"},{"issue":"9","key":"2023092719103517500_bib50","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"19","key":"2023092719103517500_bib51","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023092719103517500_bib52","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2023092719103517500_bib53","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023092719103517500_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2023092719103517500_bib55","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.bbmt.2020.09.018","article-title":"thrombotic microangiopathy after post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"26","author":"Imus","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2023092719103517500_bib56","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2013-12-542464","article-title":"Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2023092719103517500_bib57","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","article-title":"Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and wilms tumor 1 gene expression","volume":"24","author":"Jacobsohn","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023092719103517500_bib58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023092719103517500_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/bmt.2016.265","article-title":"GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes","volume":"52","author":"Chen","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023092719103517500_bib60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/bloodadvances.2021005492","article-title":"Unrelated donor \u03b1\/\u03b2 T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia","volume":"6","author":"Leahy","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023092719103517500_bib61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.leu.2402382","article-title":"Haploidentical 'megadose' CD34+ cell transplants for patients with acute leukemia","volume":"16","author":"Martelli","year":"2002","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5639\/2081302\/blooda_adv-2023-010281-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5639\/2081302\/blooda_adv-2023-010281-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:11:16Z","timestamp":1695827476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5639\/496126\/Prospective-PTCTC-trial-of-myeloablative-haplo-BMT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":61,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010281","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}